All In Biotech

Drug Trial Radar · NCT05987371

A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

Randomized, Double-blind, Placebo-controlled, Dose Exploration, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

Last checked: Nov 20, 2026Latest source record: Apr 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Aug 23, 2023

Primary completion

Jan 16, 2024

Study completion Apr 23, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • TQC3721 suspension for inhalationDrug

    TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.

  • TQC3721 matching placebo for inhalationDrug

    Placebo without active substance.

  • Salbutamol sulfate inhalation aerosolDrug

    Salbutamol is short-acting β2 receptor agonists.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The peak of Forced Expiratory Volume in the 1st second (FEV1) (4 weeks)Time frame: From baseline to four weeks after treatment.

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Wuhan Sixth Hospital

    Wuhan, Hubei, China

  • Changsha Third Hospital

    Changsha, Hunan, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • People's Hospital of Jiangxi province

    Nanchang, Jiangxi, China

  • The first hospital of Jilin University

    Changchun, Jilin, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Mianyang Central Hospital

    Mianyang, Sichuan, China

  • Suining Central Hospital

    Suining, Sichuan, China

  • The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.